CD274 and non-small cell lung carcinoma: The strong synergy between PD1/PDL1 inhibitors and chemotherapeutic drugs will likely be the basis for treating future patients with unresectable stage III NSCLC with concurrent PD1/PDL1 inhibitors with SCRT.